Related Experiment Videos
CD4 antibody therapy and cyclosporin A differentially affect HLA-DR and ICAM-1 expression in psoriatic skin
The Journal of Investigative Dermatology
|June 1, 1992
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Simple method to predict lymphocyte collection for chimeric antigen receptor T-cell engineering.
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2025
A concept for integrated care pathways for atopic dermatitis-A GA2 LEN ADCARE initiative.
Clinical and translational allergy·2023
Sensitivity of PM10 oxidative potential to aerosol chemical composition at a Mediterranean urban site: ascorbic acid versus dithiothreitol measurements.
Air quality, atmosphere, & health·2023
[Suspected allergy to COVID-19 vaccines: A retrospective study of 320 patients].
Revue francaise d'allergologie (2009)·2023
Size segregated ionic species collected in a harbour area.
Chemosphere·2022
Quantification of the impact of port activities on PM10 levels at the port-city boundary of a mediterranean city.
Journal of environmental management·2020
EGFR activity governs stage-dependent fibrotic responses in recessive dystrophic epidermolysis bullosa.
The Journal of investigative dermatology·2026
Vitiligo-associated variants and genes beyond immune-related loci: A genome-wide association and Mendelian randomization meta-analysis.
The Journal of investigative dermatology·2026
Endothelial AHR-APLNR signaling preserves vascular glycocalyx integrity and limits neutrophil-driven skin injury during local MRSA infection.
The Journal of investigative dermatology·2026
IL-31 targets the hair follicle bulge across species and delays plucking-induced anagen in mice.
The Journal of investigative dermatology·2026
Identification of Homing Receptors and Activation-Linked Surface Antigens on Human Mast Cells and Basophils.
The Journal of investigative dermatology·2026
Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study.
The Journal of investigative dermatology·2026